TABLE 2.
Tumor cell cycle characteristicsa
| Tumor type and mouse genotype | Treat- mentb | No. of tumors | Mean % of cells ± SEM in:
|
||
|---|---|---|---|---|---|
| G1 phase | S phase | G2/M phase | |||
| Salivary | |||||
| ras/p53+/+ | None | 15 | 93.8 ± 0.9 | 4.5 ± 0.6 | 1.7 ± 0.3 |
| L-744,832 | 4 | 95.4 ± 1.8 | 3.4 ± 1.4 | 1.2 ± 0.5 | |
| Doxorubicin | 6 | 97.8 ± 0.3 | 1.1 ± 0.2 | 1.1 ± 0.4 | |
| ras/p53−/− | None | 18 | 84.8 ± 1.5 | 10.5 ± 1.4 | 4.7 ± 0.7 |
| L-744,832 | 7 | 94.5 ± 2.2 | 2.7 ± 0.8 | 2.7 ± 1.4 | |
| Mammary | |||||
| MMTV–v-Ha-ras | None | 8 | 96.3 ± 0.8 | 2.3 ± 0.4 | 1.4 ± 0.6 |
| ras/myc | None | 15 | 88.8 ± 0.9 | 8.5 ± 0.7 | 2.7 ± 0.2 |
| L-744,832 | 12 | 92.4 ± 1.5 | 5.9 ± 1.3 | 1.7 ± 0.3 | |
a
Mice were treated as described in Table 1, footnote a, and Materials and Methods. G1-, S-, and G2/M-phase fractions based on flow cytometry analysis of propidium iodide-stained tumor cells are shown for salivary and mammary tumors.
b
L-744,832 was administered at 40 mg kg−1/day, and doxorubicin was administered at 10 mg kg−1.